Kurz gefasst
Fachartikel in der Zeitschrift Practical Neurology, online erschienen am 13.11.2026. Verfasst von A Fo Ben.
Abstract (Originalsprache)
A phase 3 trial of rituximab vs ocrelizumab in newly diagnosed relapsing-remitting MS gave a remarkably diplomatic result.Rituximab was non-inferior to ocrelizumab in suppressing MRI disease activity between 6 and 24 months.Relapse, disability and cognitive outcomes were similar, although analyses were underpowered to exclude clinically important differences.The separation came with infection rates: 82% with rituximab vs 69% with ocrelizumab.Most were mild, but with no long-term safety data.However, rituximab's lower acquisition cost looks different when including recurrent infections.Patients might end up paying the difference in coughs and antibiotics.
Zitieren
APA
Ben, A. F. (2026). Carphology. Practical Neurology, 26(6), 640-640. https://doi.org/10.1136/pn-2026-005503
Vancouver
Ben AF. Carphology. Practical Neurology. 2026;26(6):640-640. doi:10.1136/pn-2026-005503
BibTeX
@article{Ben2026,
author = {Ben, A Fo},
title = {Carphology},
journal = {Practical Neurology},
year = {2026},
volume = {26},
number = {6},
pages = {640--640},
doi = {10.1136/pn-2026-005503}
}
EUVIMED